Table 3 Correlations (r values) between change of 3D LVEF and (A) 3D myocardial deformation parameters and CHOP final doses and (B) arterial stiffness parameters and cardiac biomarkers.

From: 3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin’s lymphoma

A

3D Myocardial deformation

CHOP chemotherapy

 

3D LVEF

LS

CS

RS

AS

C

H

O

P

 

0.703*

0.433*

0.388*

0.571*

− 0.165

− 0.566*

− 0.188

− 0.112

B

Arterial stiffness

Cardiac biomarkers

3D LVEF

PWV

 

β index

Ep

AC

WI

NA

AIX

NT-pro-BNP

 

− 0.637*

− 0.233

− 0.531*

− 0.340*

− 0.337*

− 0.584*

− 0.188

− 0.228*

− 0.182

  1. AC arterial compliance; AIX augmentation index; AS area strain; C cyclophosphamide; CS circumferential strain; Ep Young modulus of stiffness; H hydroxydaunorubicin (doxorubicin); LS longitudinal strain; LVEF left ventricular ejection fraction; NA negative area; NT-pro-BNP N-terminal pro-brain natriuretic peptide; O oncovin (vincristine); P prednisone; PWV pulse wave velocity; RS radial strain; Tn I troponin I; WI wave intensity.
  2. *p < 0.05.
Back to article page